ImmunoGen, Inc. (NASDAQ:IMGN) Q1 2022 Results Conference Call May 6, 2022 8:00 AM ET

Company Participants

Courtney O'Konek - Senior Director, Corporate Communications

Mark Enyedy - President, CEO

Anna Berkenblit - CMO

Kristen Harrington-Smith - Chief Commercial Officer

Susan Altschuller - CFO

Conference Call Participants

Boris Peaker - Cowen

Kelly Shi - Jefferies

Etzer Darout - BMO Capital Markets

Jessica Fye - JPMorgan

John Newman - Canaccord

Joe Catanzaro - Piper Sandler

Michael Schmidt - Guggenheim

Andy Hsieh - William Blair

Jonathan Chang - SVB Securities

Operator

Good morning and welcome to ImmunoGen's First Quarter 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.

At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications. Please go ahead.

Courtney O'Konek

Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent progress and first quarter 2022 financial results. This press release and a recording of this call can be found under the Investors & Media section of our website at immunogen.com.

With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; Kristen Harrington-Smith, our Chief Commercial Officer; and Susan Altschuller, our CFO. During today's call, we will review recent accomplishments for the business, our Q1 financial results and highlight upcoming anticipated events.

We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially, please consult the risks outlined in our press release issued this morning in the Risk Factors section of our most recent annual report on Form 10-K and in our other SEC filings, which are available at sec.gov and immunogen.com.

And with that, I'll turn the call over to Mark.

Mark Enyedy

Good morning, and thank you for joining us today. Building on the strong SORAYA data and capital raise late last year, we've continued to make excellent progress in 2022. Our top priority is to gain approval for mirv monotherapy in patients with folate-receptor alpha high, platinum-resistant ovarian cancer, and we recently achieved 2 critical milestones to that end: the presentation of results from our positive pivotal SORAYA trial at SGO and the submission of the BLA to FDA for potential accelerated approval.

As we progress towards our goal of becoming a global fully integrated oncology company, since the start of the year, we've also continued enrollment in the confirmatory Phase III MIRASOL and Phase II PICCOLO studies with mirv monotherapy, expanded our commercial team and accelerated launch preparations in anticipation of a mirv approval, further accrued patients in our pivotal CADENZA study of pivek and BPDCN, initiated expansion cohorts in both relapsed and frontline AML patients combining pivek with azacitidine and venetoclax and progressed our earlier-stage programs, IMGC936 and IMGN151.